Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Sells 8,637 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 8,637 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $19.98, for a total transaction of $172,567.26. Following the completion of the sale, the chief financial officer now directly owns 73,849 shares in the company, valued at $1,475,503.02. This represents a 10.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Kory James Wentworth also recently made the following trade(s):

• On Monday, September 9th, Kory James Wentworth sold 3,195 shares of Entrada Therapeutics stock. The stock was sold at an average price of $14.97, for a total transaction of $47,829.15.

Entrada Therapeutics Stock Performance

TRDA opened at $19.04 on Friday. The stock has a market capitalization of $712.48 million, a P/E ratio of 11.97 and a beta of -0.26. The company’s 50-day simple moving average is $16.62 and its two-hundred day simple moving average is $15.85. Entrada Therapeutics, Inc. has a 52-week low of $10.75 and a 52-week high of $20.49.

Entrada Therapeutics (NASDAQ:TRDA) last posted its earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.90. The business had revenue of $94.69 million for the quarter, compared to analysts’ expectations of $55.00 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. Research analysts forecast that Entrada Therapeutics, Inc. will post 1.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Entrada Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TRDA. Allspring Global Investments Holdings LLC lifted its stake in Entrada Therapeutics by 427.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock valued at $209,000 after acquiring an additional 11,965 shares during the period. Vanguard Group Inc. lifted its stake in shares of Entrada Therapeutics by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock worth $15,288,000 after purchasing an additional 13,742 shares during the period. Acadian Asset Management LLC bought a new position in shares of Entrada Therapeutics in the 1st quarter worth approximately $79,000. Bank of New York Mellon Corp lifted its stake in shares of Entrada Therapeutics by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock worth $1,787,000 after purchasing an additional 14,838 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of Entrada Therapeutics by 25.3% in the 2nd quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock worth $526,000 after purchasing an additional 7,452 shares during the period. Institutional investors own 86.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on TRDA shares. Oppenheimer upped their target price on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 6th. HC Wainwright increased their price objective on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.